title: Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial.
abstract: BACKGROUND
  Repletion of lean body mass (LBM) that patients lose in human immunodeficiency virus (HIV) infection has proved difficult. In healthy, HIV-seronegative men, synergy between progressive resistance exercise (PRE) and very high-dose testosterone therapy has been reported for gains in LBM and muscle strength.
  
  
  OBJECTIVE
  To determine whether a moderately supraphysiologic androgen regimen, including an anabolic steroid, would improve LBM and strength gains of PRE in HIV-infected men with prior weight loss and whether protease inhibitor antiretroviral therapy prevents lean tissue anabolism.
  
  
  METHODS
  Double-blind, randomized, placebo-controlled trial; post hoc analysis for effect of HIV-protease inhibitor therapy conducted from January to October 1997.
  
  
  METHODS
  Referral center in San Francisco, Calif.
  
  
  METHODS
  Volunteer sample of 24 eugonadal men with HIV-associated weight loss (mean, 9% body weight loss), recruited from an AIDS clinic and by referral and by advertisement.
  
  
  METHODS
  For 8 weeks, all subjects received supervised PRE with physiologic intramuscular testosterone replacement (100 mg/wk) to suppress endogenous testosterone production. Randomization was between an anabolic steroid, oxandrolone, 20 mg/d, and placebo.
  
  
  METHODS
  Lean body mass, nitrogen balance (10-day metabolic ward measurements), body weight, muscle strength, and androgen status.
  
  
  RESULTS
  Twenty-two subjects completed the study (1 1 per group). Both groups showed significant nitrogen retention and increases in LBM, weight, and strength. The mean (SD) gains were significantly greater in the oxandrolone group than in the placebo group (5.6 [2.1] vs 3.8 [1.8] g of nitrogen per day [P=.05]; 6.9 [1.7] vs 3.8 [2.9] kg of LBM [P=.005]; greater strength gains for various upper and lower body muscle groups by maximum weight lifted [P = .02-.05] and dynamometry [P = .01 -.05]). The mean (SD) high-density lipoprotein cholesterol level declined 0.25 (0.14) mmol/L (9.8 [5.4] mg/dL) significantly in the oxandrolone group (P < .001 compared with placebo). Results were similar whether or not patients were taking protease inhibitors. One subject in the oxandrolone group discontinued the study because of elevated liver function test results.
  
  
  CONCLUSIONS
  A moderately supraphysiologic androgen regimen that included an anabolic steroid, oxandrolone, substantially increased the lean tissue accrual and strength gains from PRE, compared with physiologic testosterone replacement alone, in eugonadal men with HIV-associated weight loss. Protease inhibitors did not prevent lean tissue anabolism.
authors: Department of Nutritional Sciences, University of California, Berkeley, USA.
authors: A
authors: A
authors: Strawford
authors: T
authors: T
authors: Barbieri
authors: M
authors: M
authors: Van Loan
authors: E
authors: E
authors: Parks
authors: D
authors: D
authors: Catlin
authors: N
authors: N
authors: Barton
authors: R
authors: R
authors: Neese
authors: M
authors: M
authors: Christiansen
authors: J
authors: J
authors: King
authors: M K
authors: MK
authors: Hellerstein
mesh_terms: D000328:Adult; D045930:Anabolic Agents / Q000627:therapeutic use*; D001774:Blood Chemical Analysis; D001823:Body Composition / Q000187:drug effects*; D004311:Double-Blind Method; D002149:Energy Intake; D004734:Energy Metabolism; D005058:Eunuchism / Q000150:complications* / Q000188:drug therapy; D015444:Exercise; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D019247:HIV Wasting Syndrome / Q000150:complications* / Q000188:drug therapy*; D020249:Hormone Replacement Therapy; D006801:Humans; D008297:Male; D009142:Musculoskeletal Physiological Phenomena / Q000187:drug effects; D010074:Oxandrolone / Q000627:therapeutic use*; D011446:Prospective Studies; D011788:Quality of Life; D013739:Testosterone / Q000627:therapeutic use*
chemical_list: D045930:Anabolic Agents; D017320:HIV Protease Inhibitors; D013739:Testosterone; D010074:Oxandrolone